eCommons@AKU
Section of Neurology

Department of Medicine

10-14-2020

Consequences of a missed history: A case of antidepressant
discontinuation syndrome
Sajid Hameed
Mukesh Kumar
Piyush Puri
Fnu Sapna
Pal Satyajit Singh Athwal

Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_med_neurol
Part of the Nervous System Diseases Commons, and the Neurology Commons

Open Access Case
Report

DOI: 10.7759/cureus.10950

Consequences of a Missed History: A Case of
Antidepressant Discontinuation Syndrome
Sajid Hameed 1 , Mukesh Kumar 2 , Piyush Puri 3 , FNU Sapna 4 , Pal Satyajit Singh Athwal 5
1. Neurology, Aga Khan University, Karachi, PAK 2. Neurology, Shaheed Mohtarma Benazir Bhutto Medical University,
Larkana, PAK 3. Internal Medicine, Al-Falah School of Medical Sciences and Research Center, Faridabad, IND 4.
Internal Medicine, Lal Medical Center, Larkana, PAK 5. Internal Medicine, Saraswathi Institute of Medical Sciences,
Hapur, IND
Corresponding author: Piyush Puri, puri.piyush777@gmail.com

Abstract
Antidepressant discontinuation syndrome (ADDS) is reported to occur in almost 30-50% of the patients who
take antidepressants for a duration of at least four to six weeks and then suddenly discontinue the drug.
Since there is an increase in the use of antidepressants for various reasons by general practitioners, patient
education about when and how to discontinue a drug is not acknowledged enough. It is reported to occur
with the use of different classes of antidepressants - selective serotonin reuptake inhibitor (SSRI),
monoamineoxidase inhibitor (MAOI), tricyclic antidepressants (TCAs), and atypical antipsychotics like
risperidone, trazodone, clozapine, and venlafaxine. Slow tapering off the drugs has also caused ADDS.
Symptoms start within two to four days of quitting the drug and are usually mild lasting for two to four
weeks (can persist for six to 12 months) but could be severe enough leaving the patient
nonambulatory. Here, we represent a case of a 55-year-old female who presented to the outpatient clinic
with complaints of headache, vomiting, and diarrhea. The patient had 10 to 12 episodes of watery diarrhea
every day and bilateral, continuous, pressing headache associated with multiple episodes of non-projectile
vomiting. She was investigated for ultrasound sonography (USG) abdomen, CT head, and lab investigations
which turned around to be normal. A follow-up visit with detailed history revealed she suddenly stopped
taking escitalopram after six months by herself without tapering off the dose, two days before the onset of
symptoms. Escitalopram was reinstated and the symptoms started to resolve in two to three days. All the
unnecessary investigations and treatment could have been prevented if the proper history was taken and
revealed at the initial visit.
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Introduction
Depression is of prime importance to the overall global burden of diseases. Globally, it affects more than 264
million people of all age groups [1]. Antidepression drugs are used not only for depression but sundry other
disorders like general anxiety disorder (GAD), obsessive-compulsive disorder (OCD), eating disorders, posttraumatic stress disorder (PTSD), schizophrenia, neuropathic pain, etc. and hence there is an upsurge in the
use of typical and atypical antidepression drugs from a decade ago [2]. New cases of depression are twice as
high in women than men in the younger age group (14-25 years) [3].
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Antidepressant discontinuation syndrome (ADDS) was first reported with the use of imipramine (a tricyclic
antidepressant) shortly after it was first clinically used [4]. Symptoms of discontinuation syndrome are
reported to occur more in drugs with a shorter half-life than in drugs with a longer half-life [5]. A mnemonic,
FINISH, has been devised to recognize clinical symptoms of ADDS so that it is not left obscured: F - Flu-like
symptoms (headache, dizziness), I - Insomnia, N - Nausea, I - Imbalance, S - Sensory Disturbance, H Hyperarousal, with other clinical features like electric shock-like sensations (brain zap), myalgia, insomnia,
blurred vision, amnesia, disorientation, diarrhea, depersonalization, depressive mood, increased suicidal
thoughts, etc., which could mimic rebound depression [6].
Mild symptoms usually lead to misdiagnosis and unnecessary investigations and treatment. Education about
this common and likely underrecognized clinical phenomenon will help prevent future episodes and
minimize the risk of misdiagnosis. Patients are enticed to discontinue their drugs once they start feeling
better and this could lead to an early relapse of the illness as well as increased chances of ADDS. Here, in
this case, we emphasize the importance of detailed history taking and early diagnosis of ADDS, which
should be managed at the earliest else it leads to misdiagnosis with unnecessary interventions.

Case Presentation
We present a case of a 55-year old female who presented to the outpatient clinic with a three-day history of
abdominal cramps, headache, and diarrhea. The headache was continuous, bilateral diffuse, pressing in
character, moderate in intensity with intermittent severe exacerbations. It was associated with nausea and

How to cite this article
Hameed S, Kumar M, Puri P, et al. (October 14, 2020) Consequences of a Missed History: A Case of Antidepressant Discontinuation Syndrome.
Cureus 12(10): e10950. DOI 10.7759/cureus.10950

multiple episodes of non-projectile vomiting. There was no history of fever, photophobia, phonophobia,
lacrimation, vision changes, weight loss, joint pain, limb weakness, or numbness. There was no history of
similar headaches in the past. The patient had watery diarrhea about 10 to 12 times a day. There was no pus
or blood in it. On past medical history, she had been diagnosed with a generalized anxiety disorder for which
she was prescribed escitalopram (an SSRI), which she had stopped after taking for six months. There was no
history of smoking, alcohol, or illicit drug use. She was married with four children.
The physical examination was within normal limits, except exaggerated bowel sounds. Meningeal signs were
absent. There was no fever or papilledema. She was investigated and everything came out normal, including
cranial magnetic resonance imaging (MRI) (Figure 1, 2), ultrasound abdomen, and baseline laboratory
investigations including the liver function tests and blood cultures.

FIGURE 1: Patient's normal MRI cranium
No ventriculomegaly was seen. No focal, hyperdense/hypodense lesions were seen.
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FIGURE 2: Normal MRI of the skull

On a follow-up visit after four days, a repeat drug history revealed that she has suddenly stopped
escitalopram by herself without tapering the dose, only two days preceding these symptoms. We restarted
escitalopram and all her symptoms were resolved within three days. A diagnosis of antidepressant
discontinuation syndrome was made.

Discussion
The pathophysiology of ADDS is still largely unknown and the symptoms affecting sleep, balance,
gastrointestinal tract, and sensory system are thought to be due to an imbalance among the norepinephrine,
cholinergic, and serotonin neurotransmitters [7]. It is by and large related to the half-life of the drug and the
patient’s rate of metabolism, with symptoms more reported on discontinuation of paroxetine than
fluoxetine (paroxetine has a shorter half-life than fluoxetine) [8]. Some researchers have suggested the role
of genetics in the pathophysiology [9]. A finding in a clinical study shows the involvement of C(-1019) G
polymorphism of the serotonin 5-HT1A receptor gene in the occurrence of paroxetine discontinuation
syndrome [9]. The newer antidepressant medications that are used for anxiety disorder without any
supporting evidence in the efficacy of antidepressants have a similar dependence problem to
benzodiazepines, although benzodiazepines are used much less for treating anxiety disorders, studies have
shown that benzodiazepines have better efficacy in controlling panic attacks and cause less antidepression
discontinuation syndrome symptoms and hence the role of the benzodiazepines should be thoroughly
reexamined [10].
Some researchers have reported that ADDS occurs more in patients with early-onset dysthymic syndrome
and it tends to affect females more [11]. Also, reports suggest that there is no difference between
discontinuation symptoms when antidepressants are used for different disorders like depression and anxiety
disorder and reports also suggest that longer duration of treatment is not directly related to more severe
discontinuation syndrome symptoms [12].
Increased off-label use of antidepressants like in sexual dysfunction, insomnia, migraine, and premenstrual
syndrome, especially by primary care physicians, is associated with an increased incidence of antidepression
discontinuation symptoms [13]. Multiple case reports demonstrate a similarity between the symptoms of
ADDS caused by SSRI and TCA but the problems related to movement (Parkinsonism), sleep disturbances,
and GI symptoms are more closely related to the discontinuation of TCAs [14].

Conclusions
This case report highlights the importance of differential diagnosis of antidepressant discontinuation

2020 Hameed et al. Cureus 12(10): e10950. DOI 10.7759/cureus.10950

3 of 4

syndrome (ADDS) even when no psychiatric symptoms are present in the patient, since the use and
prescription of antidepressant drugs has soared high in the last decade. It also highlights the importance of a
detailed history taking. As in our case, a detailed drug history on the first visit could have avoided
unnecessary investigations and follow-up. Also, when prescribed an antidepressant, the patient should be
well educated about the disease, drug dosage, and relapse/withdrawals on abrupt discontinuation.
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